A Comparative Analysis of the Effectiveness, Usability, Uptake, and Acceptability of an Educational Website and a Mobile Health Application Prototype in Improving Knowledge on Oral Cancer

Introduction: Oral cancer is a malignant neoplastic disease affecting the lip, oral cavity (mouth) and/or the oropharynx. Despite the intense and diverse public health interventions on oral cancer prevention, the global prevalence rates of oral cancer and its major risk factors are still very high. Hence, oral cancer is an issue of serious global health importance.
Aim: To test and compare the effectiveness, usability, uptake, and acceptability of an educational website and a mobile health application prototype on oral cancer in improving oral cancer knowledge among university students.
Methods: This study will adopt a randomised control trial design, and it will be conducted among 75 first-year bachelor's degree students from five universities across two continents: University of Rwanda (Rwanda, Africa), Usmanu Danfodiyo University (Nigeria, Africa), University of Peradeniya (Sri Lanka, Asia), University of Ibadan (Nigeria), and Saveetha University (India, Aisa). The study participants will be in three groups (Group 1, Group 2, and Group 3). The participants in Group 1 will be the control group (n = 25 participants; 5 participants from each university); that is the group that will not receive an educational intervention. However, those in Group 2 (n = 25 participants; 5 participants from each university) will receive a web-based educational intervention on oral cancer while those in Group 3 (n = 25 participants; 5 participants from each university) will receive an app-based educational intervention on oral cancer. Pretest survey and posttest survey will be done for all participants. The data collected will be statistically analysed using the Statistical Package for Social Sciences (SPSS) version 28 software. Descriptive statistics will be done for all variables while inferential statistics (analysis of variance) will be done to test for associations between variables of interest.
Conclusion: The findings of this study will determine the effectiveness, usability, uptake, and acceptability of the tested digital intervention tools.

开始日期2025-01-05

申办/合作机构

University of Rwanda

[+4]

NCT06780904

/ RecruitingN/A

Comparing the Efficacy of Dry Needling Combined with Passive Stretching and Muscle Energy Technique on Upper Trapezius Myofascial Trigger Points Associated with Neck Pain

The goal of this clinical trial is to assess and compare the efficacy of dry needling (minimally invasive treatment by using a tiny needle) combined with two types of stretching techniques in patients with neck pain for more than 3 months. The main questions it aims to answer are:
Which combination of treatment will 1.give faster relief of pain? 2.improve neck range of motion? and 3.improve disability level of a person with neck pain.
Participants who are interested will be selected according to eligibility criteria. Participants will be divided into two groups. Initially researcher will assess and interview the participants. Two groups will receive two different combinations of interventions. Pre and post measurements will be obtained and then treatment efficacy will be assessed.

开始日期2024-09-01

申办/合作机构

University of Peradeniya

SLCTR/2024/029

/ RecruitingN/A

Effects of functional electrical stimulation (FES) for the motor functions of upper limb and activities of daily living (ADLs) in acute and sub-acute stroke patients.

开始日期2024-08-30

申办/合作机构

University of Peradeniya

100 项与 University of Peradeniya 相关的临床结果

登录后查看更多信息

0 项与 University of Peradeniya 相关的专利（医药）

登录后查看更多信息

4,113

项与 University of Peradeniya 相关的文献（医药）

2025-12-31·Journal of the International Society of Sports Nutrition

Improvement of sports nutrition knowledge by a dual method education program in track and field athletes: a randomized controlled trial

Article

作者: Kalupahana, Nishan Sudheera ; Nanayakkara, Indu ; Weerasinghe, Kalani ; Jayawardena, Ranil ; Hills, Andrew P. ; Madhujith, Terrence

BACKGROUND:

Athletes with strong sports nutrition knowledge are believed to have sound nutritional practices and better performance. This study aimed to evaluate the effectiveness of a dual-method personalized nutrition education program in improving sports nutrition knowledge (SNK) among Sri Lankan track and field athletes.

METHODS:

This parallel-group, randomized controlled trial recruited national-level track and field athletes aged 18 and above. The intervention group (IG) received personalized sports nutrition consultations at 0, 4^th, and 8^th weeks, along with online educational materials via WhatsApp from weeks 10 to 16, while the control group (CG) did not receive any intervention. A per-protocol analysis was followed, and t-tests were used to compare the means.

RESULTS:

Of the 30 participants enrolled, 13 from IG and 14 from CG completed the study. Following the 16-week intervention, the IG demonstrated significant improvements in total nutrition knowledge (TNK) relative to the CG (IG: 34.41 ± 4.15 vs. CG: 20.96 ± 4.38; p = 0.01), with significant increases in general nutrition knowledge (GNK) (IG:24.54 ± 3.66 vs. CG:15.64 ± 2.33; p = 0.004) and SNK (9.87 ± 3.87 vs. 5.32 ± 4.07; p = 0.006). Changes in TNK were also significantly greater in the IG compared to the CG; (IG:9.45 ± 0.10 vs. CG: -2.63 ± 0.37; p < 0.0001), GNK (IG:4.47 ± 0.08 vs. CG: -1.28 ± 0.09; p < 0.0001), and SNK (IG:4.99 ± 0.72 vs. CG: -1.25 ± 0.74; p < 0.0001).

CONCLUSIONS:

The 16-week dual-method nutrition education intervention was effective in improving TNK, GNK, and SNK among track and field athletes in Sri Lanka.

TRIAL REGISTRATION:

This trial is registered at the Sri Lanka Clinical Trials Registry (SLCTR/2024/013), Universal Trial Number (UTN): U1111-1304-8890 on 10 April 2024.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Impact of a clinical pharmacy intervention on medication adherence and the quality use of medicines in patients with acute coronary syndrome: a single centre nonrandomised controlled clinical trial

Article

作者: Coombes, I D ; Mohamed, F ; Gawarammana, I ; Bagyawantha, N M Y

Background:

Acute coronary syndrome is a major global disease burden with high morbidity and mortality. This study aims to assess the impact of clinical pharmacy interventions on improving the quality use of medicines and drug-related problems in acute coronary syndrome patients.

Methods:

An open, prospective, controlled, nonrandomised clinical trial was conducted at the Teaching Hospital, Peradeniya, Sri Lanka. Consenting patients were recruited and divided into control and intervention groups. Medication history, medication adherence and drug-related problems were assessed. The intervention group received clinical pharmacy interventions for six months. Improvements in medication adherence, discharge medication appropriateness, reduction of hospital readmissions for six months, and responses from the healthcare team's awareness and perception on clinical pharmacy services were recorded.

Results:

Both groups (control - 180 patients, intervention - 185 patients) showed poor medication adherence at baseline. Medication adherence improved significantly after 6-months post-discharge in the intervention group compared to the control group (49.3% vs 18.8%). The clinical pharmacists successfully identified drug-related problems and provided suggestions for resolving them. The treating team accepted the majority (60%) of these suggestions. Discharge medication appropriateness in the intervention group was significantly higher compared to the control group. There was no significant difference in hospital readmissions related to cardiovascular disorders between the groups. Most doctors and nurses were aware of clinical pharmacists but none of them had previously worked with one.

Conclusion:

Clinical pharmacist-led interventions significantly improved medication adherence and appropriateness, underscoring the added value of clinical pharmacists in a multidisciplinary healthcare team. While most doctors and nurses were aware of clinical pharmacists, none of them had prior experience working with them, emphasising an opportunity to foster greater multidisciplinary integration for improved health outcomes. Overall findings highlight the potential role of clinical pharmacists in enhancing good patient outcomes and improving real-world patient care.

2025-09-01·WATER RESEARCH

Short- and long-read metagenomics uncover the mobile extended spectrum β-lactamase (ESBL) and carbapenemase genes in hospital wastewater in Sri Lanka

Article

作者: Han, Ziming ; Cooray, Titus ; Zhang, Yu ; Hu, Chengzhi ; Karunaratne, S H P Parakrama ; Guruge, Shashika Kumudumali ; Yang, Min ; Chandrajith, Rohana

The antibiotic resistance issue in low- and middle-income countries has drawn global concern. This study presents the first metagenomic investigation of antibiotic resistance genes (ARGs) in hospital and municipal wastewater treatment plants (WWTPs) in Sri Lanka, using Illumina short-read and Nanopore long-read sequencing. Samples from three representative WWTPs receiving hospital and/or municipal wastewater (domestic generated) were collected from four districts in Sri Lanka, and as a comparison, wastewater directly discharged without treatment was also taken. ARG abundance was significantly higher in hospital wastewater (7.22 copies/cell) than in municipal wastewater (2.33 copies/cell), and greatly decreased by 82 % and 93 % after treatment processes, respectively. Similar trends were observed for mobile genetic elements. The prevalent subtypes of clinically relevant extended spectrum β-lactamase (ESBL) and carbapenemase genes in hospital wastewater were bla_OXA, bla_GES, bla_VEB and bla_TEM, whereas bla_CTX-_M and bla_NDM were less dominant, which indicated the potential unique distribution pattern of ESBL and carbapenemase genes in Sri Lanka. Using long-read metagenomics, bacterial host range and genetic locations (plasmid or chromosome) of ARGs in sludge samples were predicted. Diverse pathogenic host taxa (Pseudomonas, Streptococcus, Salmonella and Escherichia) and a higher plasmid proportion were identified in the hospital WWTP (39.8 % vs. 21.5 % in the municipal WWTP). Detected mobile genetic contexts in this study, IS6100-sul1-bla_OXA-329-bla_GES-5-bla_GES-5-intI1 and ISKpn6-bla_KPC-2-ISKpn7-ISPsy42, were also common in antibiotic-resistant plasmids in Enterobacteriaceae from different countries. These data will serve to expand the inventory of global ARG epidemiology. Also, the finding emphasizes that the wastewater treatment projects, especially in healthcare facilities, are vital for reducing clinically relevant ARG discharge to the environment. Further monitoring using advanced meta-omics approaches is crucial to assess potential ARG risks and optimize control strategies for improving human and ecosystem health in Sri Lanka.

项与 University of Peradeniya 相关的新闻（医药）

2021-01-28

·BioSpace

Venatorx Pharmaceuticals Names New Head of Regulatory Affairs

Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx’s global regulatory strategy for its clinical and pre-clinical anti-infectives programs MALVERN, Pa.--(BUSINESS WIRE)-- Venatorx Pharmaceuticals today announced that Chitrananda Abeygunawardana, Ph.D. has been named Vice President, Regulatory Affairs. With nearly 25 years’ experience in pharmaceutical research, regulatory affairs and compliance, Dr. Abey will be responsible for developing and executing all regulatory strategies and tactics for Venatorx’s antibacterial and antiviral programs including interacting with health authorities and managing clinical trial applications worldwide. This press release features multimedia. View the full release here: Chitrananda Abeygunawardana, Ph.D. -- Vice President, Regulatory Affairs at Venatorx Pharmaceuticals, Inc. (Photo: Business Wire) “We are proud to continue to attract the best and brightest minds to Venatorx to support our mission to bring lifesaving antibiotics and antiviral medicines to patients around the globe,” said Christopher J. Burns, Ph.D., President and CEO of Venatorx. “Dr. Abey will play a critical role in advancing our antibiotic and antiviral programs from benchtop to bedside. I look forward to working with him as we progress our programs to market.” “We have witnessed first-hand the colossal impact a global pandemic can have on our way of life,” said Dr. Abey. “I am excited by the opportunity to be part of a company that is addressing critical unmet medical needs for patients, and working hard every day to thwart what could be the next global pandemic—antimicrobial resistance.” Prior to joining Venatorx, Dr. Abey was Executive Director of Merck Global Regulatory Affairs and Clinical Safety (GRACS) where he led the development of Merck’s pneumococcal vaccine strategy, and developed the regulatory strategies to support new drug development and licensures. During his tenure at Merck, Dr. Abey was a key contributor in the development of strategies for multiple anti-infectives including vaccines, antivirals and antifungals, as well as immune-oncology, representing every stage of drug development from pre-clinical concept to life cycle management of approved products. Dr. Abey has extensive experience in formulating late stage clinical and regulatory strategy to maximize value through optimal labeling indications and content, and in leading discussions with the FDA (CBER, CDER, & CDRH) and representing Merck in discussions with other key ex-US Agencies (EMA, Health Canada, PMDA, PEI, CFDA, etc.). In addition, Dr. Abey has extensive expertise in analytical and manufacturing aspects of vaccines and biologics, cGMPs, devices, content labeling, and manufacturing investigations. Dr. Abey received his Ph.D. in Chemistry from UMBC in Baltimore, Maryland and his B.S. in Chemistry from the University of Peradeniya in Sri Lanka. In addition, he was a member of the Research Faculty at Johns Hopkins School of Medicine. About Venatorx Pharmaceuticals Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. For more information, please visit . View source version on businesswire.com:

疫苗

100 项与 University of Peradeniya 相关的药物交易

登录后查看更多信息

100 项与 University of Peradeniya 相关的转化医学

登录后查看更多信息